Cohere Health Strengthens Clinical Expertise with Addition of Dr. Paul Johnson to its Medical Advisory Board

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Experienced spine surgeon joins Cohere Health Medical Advisory Board to grow and enhance AI-powered clinical intelligence solutions

BOSTON, April 16, 2025 /PRNewswire/ — Cohere Health®, the leader in clinical intelligence solutions for health plans, announces the addition of Dr. Paul Johnson to its esteemed Medical Advisory Board (MAB). Dr. Johnson, an orthopedic spine surgeon with over 30 years of experience, joins a distinguished group of physicians from the nation’s top hospitals and health systems, reinforcing Cohere Health’s deep clinical foundation in prior authorization (PA) innovation.

“We firmly believe the physician’s voice is essential to transforming prior authorization into a process that enhances, rather than hinders, patient care,” said Dr. Brian Covino, chief medical officer at Cohere Health. “As AI continues to face scrutiny in healthcare, Cohere Health’s extensive physician team plays a key role in ensuring clinical expertise remains core to our solutions. In particular, our Medical Advisory Board, including Dr. Johnson, helps shape our proprietary clinical policies and actively engages their respective medical societies, validating that said policies are aligned with the latest evidence-based recommendations. Dr. Johnson’s expertise will help us continue to refine our differentiated, clinically driven approach.”

Dr. Johnson joins the Cohere Health Medical Advisory Board at a time when the company continues to set new standards for PA, marrying clinical intelligence with advanced technology. By harnessing insights both from its deep clinical bench and leading societies–including the American Academy of Orthopaedic Surgeons (AAOS) and North American Spine Society (NASS), of which Dr. Johnson is an active member–Cohere Health ensures its intelligent solutions are informed by the latest evidence-based guidance and that its Medical Advisory Board comprises physicians dedicated to advancing quality care in their specialties.

“Cohere Health is redefining prior authorization by turning it into an intelligent, collaborative process that truly aligns with physicians and improves patients’ outcomes,” said Dr. Johnson. “Having been involved in the early development of Cohere’s spine clinical pathways, I’m thrilled to join the Medical Advisory Board and further contribute to this important work, ensuring utilization management continues to evolve in a way that benefits both providers and our patients.”

Cohere Health’s clinically focused approach, supported by more than 60 experienced physicians on staff in addition to its Medical Advisory Board, has had a measurable impact on both the provider prior authorization experience as well as on care outcomes. Cohere Health intelligently auto-approves up to 90% of PA requests, helping providers spend less time on manual administrative tasks and more time delivering care. The company has achieved a 93% provider satisfaction rate and provider net promoter score (NPS) of 66 as a result of its AI-driven, provider-centric workflows. Patients also benefit from significantly faster access to high-quality care aligned with clinical best practices.

Cohere Health remains committed to advancing its unique approach to intelligent prior authorization, which integrates physician and medical society expertise, improves provider collaboration and experience throughout the PA process, and ultimately results in better patient care and outcomes. For more information about Cohere Health and its expert Medical Advisory Board, visit https://coherehealth.com/our-leadership/#medical-advisory-board.

About Cohere Health
Cohere Health is a clinical intelligence company delivering AI-powered intelligent prior authorization solutions, which streamlines patients’ access to quality care by aligning their physicians and health plans for improved collaboration, transparency, and care coordination. Cohere works with nearly 600,000 providers and processes more than 12 million prior authorization requests annually, using AI to auto-approve up to 90% of requests for millions of health plan members around the country. The company was recognized twice in the Gartner® Hype Cycle™ for U.S. Healthcare Payers, is a Top 5 LinkedIn™ Startup for 2023 & 2024, and is a three-time KLAS Points of Light award recipient. Its investors include Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, and Polaris Partners.

CONTACT:
Kat Long
anthonyBarnum Public Relations
kat.long@anthonybarnum.com

Rachel Rabinowitz
Cohere Health
rachel.rabinowitz@coherehealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cohere-health-strengthens-clinical-expertise-with-addition-of-dr-paul-johnson-to-its-medical-advisory-board-302429515.html

SOURCE Cohere Health

Staff

Recent Posts

Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial

Halifax, Nova Scotia--(Newsfile Corp. - May 15, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

53 minutes ago

Mobile-health Network Solutions to Present at Sidoti Virtual Investor Conference, May 21-22, and Virtual Tech Conference, June 3-5

Singapore, Singapore--(Newsfile Corp. - May 15, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or…

2 hours ago

Vaso Corporation Announces Financial Results for First Quarter of 2025

PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading…

2 hours ago

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in…

2 hours ago

PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

2 hours ago

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed…

2 hours ago